<DOC>
	<DOCNO>NCT00767949</DOCNO>
	<brief_summary>Age-related macular degeneration ( AMD ) disease , time , destroy macula , central part retina give sharp central vision . The primary purpose study assess safety iSONEP humanize monoclonal antibody bioactive lipid , sphingosine 1-phosphate ( S1P ) .</brief_summary>
	<brief_title>Safety Study iSONEP ( Sonepcizumab/LT1009 ) Treat Neovascular Age-related Macular Degeneration</brief_title>
	<detailed_description>S1P modulate AMD-associated process angiogenesis , inflammation fibrosis . A potential strategy treat choroidal neovascularization associate AMD reduce biologically available extracellular level S1P . iSONEP highly selective S1P bind picomolar affinity . Lpath propose iSONEP would deprive many cell type ( fibroblast , pericytes , vascular endothelial cell inflammatory ) important growth survival factor thus target multiple maladaptive process exudative AMD ultimately result loss photoreceptors , support cell , visual acuity . Targeting simultaneously multiple component choroidal neovascular response novel approach potential potent `` single-targeted '' therapeutic anti-VEGF therapy .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<criteria>50 year old BCVA ETDRS letter score study eye 2057 letter use ETDRS refraction ( Snellen 20/7020/400 ) Any CNV secondary AMD study eye , classic , minimally classic occult leakage fluorescein angiography intraretinal subretinal fluid OCT Visual acuity fellow eye must 20/800 well 4 meter Able read , understand sign consent form enter study Ocular disease CNV could compromise vision study eye Systemic immunosuppressive medication/therapy ( e.g. , chemotherapy , steroid ) Uncontrolled hypertension and/or arrhythmia QT/QTc interval measurement &gt; 450 msec Cancer within last 2 year except superficial basal squamous cell skin cancer cervical carcinoma situ Have angioid streak , presume ocular histoplasmosis syndrome , myopia ( &gt; 8 diopter ) CNV secondary cause AMD Any additional ocular disease irreversibly compromise visual acuity study eye include amblyopia , anterior ischemic optic neuropathy , clinically significant diabetic macular edema severe nonproliferative diabetic retinopathy Any intraocular general surgery , include cataract surgery , within 2 month Day 1 History uveitis either eye Any ocular periocular infection within 4 week prior Day 1 Active ocular inflammation grade trace Cup disc ratio &gt; 0.8 , IOP &gt; 21 mmHg glaucoma subject treat 2 ocular hypotensive agent Previous par plana vitrectomy trabeculectomy study eye History anterior vitrectomy Inability obtain photograph , FA OCT document CNV , e.g . due medium opacity , allergy fluorescein dye lack venous access Aphakia Previous intravitreal Macugen , Avastin Lucentis ( injection drug device implantation ) study eye within 6 week triamcinolone within 6 month Receiving require chronic concomitant therapy systemic antiangiogenic treatment p.o. , parenteral ( exclude inhale steroid ) ( &gt; 5 mg ) topical corticosteroid study eye PDT within 12 week prior Day 1 Subjects take systemic anticoagulant warfarin Investigational agent device within 6 week prior Day 1 Females pregnant nursing woman child bear potential use adequate contraceptive precaution</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>wet</keyword>
	<keyword>AMD</keyword>
</DOC>